MENU
XNCR
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Xencor (XNCR) Ownership - Who owns Xencor?
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
465 North Halstead Street
Phone
+1 626 305-5900
Employees
256
Web
https://www.xencor.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
771.28M
P/E Ratio
N/A
Total Cash
497.78M
Projected Growth
N/A
Total Debt
231.95M
Revenue
110.49M
Risk (Beta)
0.97
Dividend Yield
N/A
Total Cash/Share
7.00
Total Debt/Equity
N/A
Revenue/Share
1.70 USD as % of share price
Fundamentals
XNCR
Capitalization
771M
P/E Ratio
N/A
Risk (Beta)
0.97
Dividend Yield
N/A
Total Cash
498M
Total Cash/Share
7.00
Total Debt
232M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
1.70%
Revenue
110M
ROE
N/A
Book Value
678M
P/B Ratio
1.14
Cash Flow
N/A
Earnings
-3.58
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
703K
Current Ratio
6.61
Current Revenue Per Employee
280072.00
Dividends Per Share - Security
N/A
EBITDA
-186.17M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-24.43
Shares Held By Institutions
2.27B
Shares Outstanding - Current
71.2M
Total Liabilities
278M
Total Volume MTD
N/A
Value
-1
Gain YTD
-52.829
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of therapeutics to treat autoimmune and allergic diseases, cancer and other conditions
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
465 North Halstead Street
Phone
+1 626 305-5900
Employees
256
Web
https://www.xencor.com